

Special Issue

Giant or Jumbo Phages

Message from the Guest Editors

Giant or jumbo phages are terms used to describe prokaryotic viruses with genomes >200 kb. Most giant phages have a myoviral tail structure and some have a siphoviral tail. There are no known giant podoviruses. Despite all giant phages having counterparts to the major head components present in all tailed phages, at the genome level giant phage genomes represent an astonishing amount of genetic diversity. Collectively, giant phages represent a wealth of research questions, including but not limited to their genomes, structure/assembly, novel infection strategies, ecology, evolution, and potential for applications ranging from clinical settings to industry and agriculture. We encourage the submission of manuscripts that address these gaps in knowledge. We also wish to highlight that for this issue, we will consider T4 phage as an “honorary” giant phage and welcome the submission of research manuscripts on phages with T4-like core genes or strategies. The participants of the Phages Futures Congress will enjoy 10% discount.

Guest Editors

Dr. Julie Thomas

Thomas H. Gosnell School of Life Sciences, College of Science,
Rochester Institute of Technology, Rochester, NY, USA

Dr. Lindsay Black

Department of Biochemistry and Molecular Biology, University of
Maryland School of Medicine, Baltimore, MD, USA

Deadline for manuscript submissions

closed (31 August 2020)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.8
CiteScore 7.3
Indexed in PubMed



mdpi.com/si/36995

Viruses
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.8
CiteScore 7.3
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

Director, HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2024).